09688 Overview

Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.

Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.

Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.

Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.

Morgan Stanley's Prediction: Morgan Stanley forecasts a 70-80% probability that WUXI BIO's share price will rise in the next 45 days, following a positive profit alert and management guidance indicating accelerated growth in FY2026.

Earnings Forecast Adjustment: The broker has raised its earnings forecasts for WUXI BIO from 2026 to 2030 by 4-10% and increased the target price from $45 to $50, maintaining an Overweight rating.

Recent Stock Performance: WUXI BIO's stock opened 2.71% higher and reached a peak of $44, marking a two-year high, with a trading volume of approximately 24.89 million shares.

Research Services Momentum: The company is experiencing strong momentum in research services, which is expected to enhance profitability through IP-related revenue and recent out-licensing deals with Vertex and ZAI LAB.

ZAI LAB's Current Performance: ZAI LAB is experiencing challenges that have impacted its recent performance, with a stock price decline of approximately 27% since November 6.

Long-term Growth Potential: Despite current headwinds, UBS remains optimistic about ZAI LAB's long-term growth potential, particularly regarding its key assets like Zoci and ZL-1503.

Attractive Risk-Reward Ratio: UBS believes that the development and expansion potential of ZAI LAB's products are not yet reflected in its stock price, making the risk-reward ratio attractive.

Rating and Target Price Adjustment: UBS has reiterated a Buy rating for ZAI LAB while lowering its target price from HKD33.5 to HKD20.1.